

Date and Time: 27th October – 10.30 to 17.15
28th October – 09.30 to 14.00

Minutes: Confirmed

Guideline Development Group 2: Spondyloarthritis

Place: Red Rooms, City Tower, Manchester

Present: Gary McVeigh (Chair) (GM)
Amanda Isdale (AM)
Carol McCrum (CM)
Claire Strudwicke (CS)
David Chandler (DC)
Jon Packham (JP)
Louise Warburton (LW)
Tina Hawkins (TH)

Apologies: Debbie Cook (DCo)
Issak Bhojani (IB)
Jon Packham (JP) (Day 2 only)

In attendance:

NICE Staff: Margaret Derry (MD) Kate McAllister (KM) Rachel Houten (RH)	Hugh McGuire (HM) Gabriel Rogers (GR) Louise Shires (LS) Jemma Deane (JD)	Apologies: Louise Shire (LS) (Part of day 1 only)
--	--	---

Observers:

Wesley Hubbard – NICE Information Services Team (Day 1 only)
Julia Bidonde – NICE Internal Clinical Guidelines Team (Day 1 only)

Notes: 27th October 2014

1. Introductions, matters arising and declarations of interest

GM welcomed the group, explaining the objectives for the day. Apologies were noted and the minutes of the last meeting were agreed as an accurate record.

GM noted that, due to conflicting interests, Philip Helliwell has stepped down from the GDG. His role will now be recruited to. GM also asked the group to contact MD with any suggestions of contacts to approach about outstanding vacancies for co-opted experts.

No new declarations of interest were declared with the following exceptions:

Name	Conflict	Decision
Louise Warburton	A future speaking engagement at the 4 th World Psoriasis & Psoriatic Arthritis Conference, for which there is no speaker payment.	No conflict
	A future speaking engagement with Guidelines in Practice, with the fee donated to Severn Hospice	Non-personal financial specific interest – declare & participate
Jon Packham	Attendance at an MSD sponsored 2 day, clinical academic research meeting in Birmingham ‘New Perspectives in Ankylosing Spondylitis’. MSD fund the meeting but do not influence its content.	Non-personal financial specific interest – declare & participate
	An invitation to co-present at the West Midlands ‘inside out’ meeting sponsored by Abbvie on 2/3/2015. This is non promotional disease education for professionals around psoriatic arthritis developments.	Non-personal financial specific interest – declare & participate
	Approached to be the UK chief investigator for a study into sekukinumab in PsA for Novartis (probably from Feb/March 2015) Not as yet agreed to accept this role incase of a conflict.	Personal non-financial, specific – this would create a conflict, do not go ahead
Tina Hawkins	Authored an article on subcutaneous tocilizumab which will be published in the European Journal of Hospital Pharmacy. The drug is not licensed for spondyloarthropathies. There is a small fee of £150 which will go directly to the pharmacy departments study fund.	Non-personal financial non-specific interest – declare & participate
Amanda Isdale	Attendance at the 9th International Congress on Spondyloarthroapthies 23/10-25/10/2014 Funded by Abbvie	Non personal financial, specific interest – declare & participate

GM asked the group to ensure all new declarations of interest are sent well in advance of meetings to MD.

2. Switching and sequencing update

GM updated the group on switching and sequencing of biologics. The group highlighted the importance of considering comorbidities when selecting a treatment. This will be reflected to the NICE Technology Appraisals Team.

3. Prioritising health economics

RH presented the results of the health economics prioritisation. Following discussion it was agreed that health economics will focus on RQ’s 4 and 7 to 10.

4. RQ15

KM presented the clinical reviews for the review question: *What is the effectiveness of structured exercise compared with standard care for spondyloarthritis?*

KM went through the review protocol, search strategies and included evidence used to inform these questions. The GDG discussed the evidence available and drafted recommendations.

5. Review protocols

KM talked the group through a number of review protocols. The group discussed these in turn to help finalise the inclusion and exclusion criteria for the population, intervention, comparison and outcomes.

No further business was discussed.

Notes: 28th October 2014

6. GM provided a recap of day 1 and outlined the objectives for day 2.

7. RQ17

KM presented the clinical reviews for the review question: *‘What is the effectiveness of acupuncture compared with sham acupuncture and standard care for managing spondyloarthritis?’*

KM went through the review protocol, search strategies and included evidence used to inform these questions. The GDG discussed the evidence available and drafted recommendations.

8. Review protocols

The group continued to review protocols and finalise the inclusion and exclusion criteria for the intervention, comparison and outcomes.

9. Recap of recommendations and linking evidence to recommendations

To explain how the GDG reached their recommendations, HM summarised the key details captured from discussions for each review question presented.

10. Summary of the day

GM thanked the group for their contributions and confirmed the next meeting will be held in Red Rooms, City Tower, Manchester on 16th December.